................... 84 APPENDIX 4: AMENDMENT JUSTIFICAT ION AND CHANGE LOG ................................ ..88 Heat Biologics, Inc. Viagenpumatucel -L Protocol HS110 -102 CONFIDENTIAL Amendment 6, 24 May 2019 Page 18 of 95 4.1. List of Tables Table 1: Comparison of ImPACT to Other Immunotherapies ................................ .................. 29 Table 2: Schedule of Activities (Arm 5: HS -110+ Nivolumab) ................................ ............... 51 Table 3: Schedule of Activities (Arm 6: HS -110 + Pembrolizumab +/ - Pemetrexed) ............. 53 Table 4: Investigational Product ................................ ................................